Collegium Pharmaceutical, Inc. General and Administrative Expense
Collegium Pharmaceutical, Inc. (COLL) reported General and Administrative Expense of $25.37 million for the 3-month period ending 2016-12-31, per its 10-K filed 2017-03-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2017-03-10
- Collegium Pharmaceutical, Inc. general and administrative expense for the quarter ending 2016-12-31 was $25.37M, a 220.90% increase year-over-year.
- Collegium Pharmaceutical, Inc. general and administrative expense for the quarter ending 2016-09-30 was $23.57M, a 298.97% increase year-over-year.
- Collegium Pharmaceutical, Inc. general and administrative expense for the quarter ending 2016-06-30 was $20.17M, a 587.56% increase year-over-year.
- Collegium Pharmaceutical, Inc. general and administrative expense for the quarter ending 2016-03-31 was $11.53M, a 427.22% increase year-over-year.
- Collegium Pharmaceutical, Inc. general and administrative expense for fiscal 2015 was $18.93M, a 599.63% increase from fiscal 2014.
- Collegium Pharmaceutical, Inc. general and administrative expense for fiscal 2014 was $2.71M, a 43.55% increase from fiscal 2013.
- Collegium Pharmaceutical, Inc. general and administrative expense for fiscal 2013 was $1.89M.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 3 month as first filed | General and Administrative Expense 6 month | General and Administrative Expense 9 month | General and Administrative Expense 12 month |
|---|---|---|---|---|---|
| 2016-12-31 | $25.37M 10-K · filed 2017-03-10 | $48.93M derived: sum of 2 quarters · filed 2017-03-10 | $69.11M derived: sum of 3 quarters · filed 2017-03-10 | $80.63M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2016-09-30 | $23.57M 10-K · filed 2017-03-10 | $43.74M derived: sum of 2 quarters · filed 2017-03-10 | $55.27M derived: sum of 3 quarters · filed 2017-03-10 | $63.17M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2016-06-30 | $20.17M 10-K · filed 2017-03-10 | $31.70M 10-Q · filed 2016-08-11 | $39.60M derived: sum of 3 quarters · filed 2017-03-10 | $45.51M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2016-03-31 | $11.53M 10-K · filed 2017-03-10 | $19.43M derived: sum of 2 quarters · filed 2017-03-10 | $25.34M derived: sum of 3 quarters · filed 2017-03-10 | $28.27M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-12-31 | $7.91M 10-K · filed 2017-03-10 | $13.81M derived: sum of 2 quarters · filed 2017-03-10 | $16.75M derived: sum of 3 quarters · filed 2017-03-10 | $18.93M 10-K · filed 2016-03-18 | |
| 2015-09-30 | $5.91M 10-K · filed 2017-03-10 | $8.84M derived: sum of 2 quarters · filed 2017-03-10 | $11.03M 10-Q · filed 2015-11-12 | $12.05M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-06-30 | $2.93M 10-K · filed 2017-03-10 | $5.12M 10-Q · filed 2016-08-11 | $6.14M derived: sum of 3 quarters · filed 2017-03-10 | $6.83M derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-03-31 | $2.19M 10-K · filed 2017-03-10 | $2.19M 10-Q/A · filed 2015-07-17 | $3.21M derived: sum of 2 quarters · filed 2017-03-10 | $3.89M derived: sum of 3 quarters · filed 2017-03-10 | $4.42M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | $1.02M 10-K · filed 2016-03-18 | $1.71M derived: sum of 2 quarters · filed 2016-03-18 | $2.23M derived: sum of 3 quarters · filed 2016-03-18 | $2.71M 10-K · filed 2016-03-18 | |
| 2014-09-30 | $687.00K 10-K · filed 2016-03-18 | $1.21M derived: sum of 2 quarters · filed 2016-03-18 | $1.69M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $523.00K 10-K · filed 2016-03-18 | $999.00K 10-Q · filed 2015-08-12 | |||
| 2014-03-31 | $476.00K 10-K · filed 2016-03-18 | $475.00K 10-Q/A · filed 2015-07-17 | |||
| 2013-12-31 | $1.89M 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |